ATE526313T1 - Sphingosinverbindung, verfahren zu deren herstellung und sphingomyelinaseinhibitor - Google Patents

Sphingosinverbindung, verfahren zu deren herstellung und sphingomyelinaseinhibitor

Info

Publication number
ATE526313T1
ATE526313T1 AT08721356T AT08721356T ATE526313T1 AT E526313 T1 ATE526313 T1 AT E526313T1 AT 08721356 T AT08721356 T AT 08721356T AT 08721356 T AT08721356 T AT 08721356T AT E526313 T1 ATE526313 T1 AT E526313T1
Authority
AT
Austria
Prior art keywords
sphingosine compound
production
sphingomyelinase inhibitor
compound
sphingomyelinase
Prior art date
Application number
AT08721356T
Other languages
English (en)
Inventor
Mugio Nishizawa
Hiroshi Imagawa
Jun Sakurai
Masataka Oda
Original Assignee
Otsuka Chemical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Chemical Co Ltd filed Critical Otsuka Chemical Co Ltd
Application granted granted Critical
Publication of ATE526313T1 publication Critical patent/ATE526313T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/06—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom
    • C07D213/22—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom containing two or more pyridine rings directly linked together, e.g. bipyridyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT08721356T 2007-03-09 2008-03-05 Sphingosinverbindung, verfahren zu deren herstellung und sphingomyelinaseinhibitor ATE526313T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007060950 2007-03-09
PCT/JP2008/053936 WO2008111450A1 (ja) 2007-03-09 2008-03-05 スフィンゴシン化合物、その製造方法及びスフィンゴミエリナーゼ阻害剤

Publications (1)

Publication Number Publication Date
ATE526313T1 true ATE526313T1 (de) 2011-10-15

Family

ID=39759393

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08721356T ATE526313T1 (de) 2007-03-09 2008-03-05 Sphingosinverbindung, verfahren zu deren herstellung und sphingomyelinaseinhibitor

Country Status (6)

Country Link
US (1) US8093395B2 (de)
EP (1) EP2133335B9 (de)
JP (1) JP5178707B2 (de)
AT (1) ATE526313T1 (de)
TW (1) TWI391377B (de)
WO (1) WO2008111450A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2970344A2 (de) * 2013-03-15 2016-01-20 Cerenis Therapeutics Holding SA Verfahren zur synthese von sphingomyelinen und dihydrosphingomyelinen
US9708354B2 (en) 2013-03-15 2017-07-18 Cerenis Therapeutics Holding Sa Methods for the synthesis of sphingomyelins and dihydrosphingomyelins
BR102013031043B1 (pt) * 2013-12-02 2018-03-13 Fundação Butantan Uso de compostos químicos capazes de inibir a ação tóxica das esfingomielinases d do veneno de aranhas loxosceles e composição farmacêutica compreendendo os referidos compostos
EP4265728A4 (de) * 2020-12-24 2025-08-20 Denka Company Ltd Dna-konstrukt, vektor, bakterium und verfahren zur herstellung eines polypeptids

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000086601A (ja) 1998-09-04 2000-03-28 Otsuka Pharmaceut Co Ltd セラミド誘導体
AU1548101A (en) 1999-11-24 2001-06-04 Sagami Chemical Research Center Sphingosine derivatives
JP2001213858A (ja) * 1999-11-24 2001-08-07 Sagami Chem Res Center スフィンゴシン誘導体
JP4165198B2 (ja) 2002-11-28 2008-10-15 ダイソー株式会社 スフィンゴミエリン類縁体およびその製法
JP4182910B2 (ja) 2004-03-30 2008-11-19 ダイソー株式会社 スフィンゴミエリン類縁体とその製造法

Also Published As

Publication number Publication date
JPWO2008111450A1 (ja) 2010-06-24
JP5178707B2 (ja) 2013-04-10
EP2133335B1 (de) 2011-09-28
US20100099881A1 (en) 2010-04-22
EP2133335A1 (de) 2009-12-16
US8093395B2 (en) 2012-01-10
TWI391377B (zh) 2013-04-01
EP2133335B9 (de) 2012-03-21
TW200900381A (en) 2009-01-01
WO2008111450A1 (ja) 2008-09-18
EP2133335A4 (de) 2010-12-15

Similar Documents

Publication Publication Date Title
ATE550334T1 (de) N-pyridylpiperidinverbindung, verfahren zu ihrer herstellung und schädlingsbekämpfungsmittel
WO2008126933A3 (en) Process for producing pesticidal benzamide compounds
MX363956B (es) Agente de control de plagas.
WO2008146871A1 (ja) グルココルチコイド受容体結合活性を有する、スルホン酸エステル又はスルホン酸アミド構造を導入したフェニル基を置換基として有する新規１，２，３，４－テトラヒドロキノキサリン誘導体
MY152535A (en) Novel 6-triazolopyridazinesulfanyl benzothiazole and benzimidazole derivatives, method for production thereof and application as medicaments and pharmaceutical compositions and novel use as met inhibitors
EA017861B9 (ru) Способ получения 4-оксохинолинового соединения
WO2008108378A3 (en) Bicyclic oxomorpholine derivative
MX2012008372A (es) Derivado de imidazol sustituido con cicloalquilo.
PH12012501385A1 (en) Piperazine compound having a pgds inhibitory effect
NZ596653A (en) Total synthesis of salinosporamide a and analogs thereof
ATE500212T1 (de) Bisphenol monoester
ATE526313T1 (de) Sphingosinverbindung, verfahren zu deren herstellung und sphingomyelinaseinhibitor
WO2008136378A1 (ja) 新規なスルホンアミド誘導体またはその塩
CO5611151A2 (es) Derivados de acido 4-(piperidin-1-il) piperidina-1-acetico como moduladores le 11 5rh
DE602006008962D1 (de) Verfahren zur herstellung von valsartan
WO2008003620A3 (de) Elektrochemische herstellung sterisch gehinderter amine
EA200900478A1 (ru) Жидкая пестицидная композиция, содержащая n-фенилсемикарбазоновые пестицидные соединения
BRPI0921059A2 (pt) derivados de bifenilacetamida
EA201070486A1 (ru) Усовершенствованный способ получения 2-(замещенный фенил)-2-гидроксиэтилкарбаматов
WO2008030838A3 (en) Heteroaromatic compounds having sphingosine-1-phosphate (s1p) receptor agonist biological activity
ATE444323T1 (de) Neuartige epoxidverbindungen und verfahren zu ihrer herstellung
ATE525386T1 (de) 3'-ethynylcytidinderivat
BRPI0516192A (pt) composto, e, método para a preparação de um composto
EA201000084A1 (ru) Новые соединения нафталина, способ их получения и фармацевтические композиции, содержащие их
WO2008006236A3 (en) Benzimidazoles as cooling compounds

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties